SLC5A2 and depressive symptom measurement: Similarly, Wium-Anderson et al.32 reported on the risk of incident depression in persons with T2DM previously prescribed insulin, metformin, sulfonylureas and glinides, DPP-4i, GLP-1RAs, sodium-glucose cotransporter-2 inhibitors (SGLT2i), and/or acarbose.